OSE Immunotherapeutics announced a new collaboration agreement with MAbSilico to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development. OSE Immunotherapeutics and MAbSilico entered into an initial agreement early 2020 to apply innovative AI-based solutions to six programs aiming at accelerating the characterization and optimization of monoclonal antibodies and therapeutic proteins for OSE to investigate as therapeutic agents. Through this expanded agreement, both companies reinforce and extend the scope of the collaboration to use MAbSilico software for ten additional development programs of antibody drugs in immuno-oncology, inflammation and autoimmune diseases for OSE. Furthermore, both companies are bringing together their unparalleled expertise in the field of AI and antibody-based therapies to develop a disruptive computational in silico Antibody Discovery and Design platform combining OSE’s database and expertise with MAbSilico’s AI-tools. MAbSilico software, including AI, numerical simulation and data mining, is being used to guide therapeutic antibody discovery, help reduce the risk of failure and accelerate the preclinical development process of antibody drug candidates, with the objectives of speeding up the start of clinical testing.